Forte Biosciences, Inc.: 5%+ holders

As of November 8, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Forte Biosciences, Inc. The largest reported stake is JANUS HENDERSON GROUP Ltd.'s, at 9.3%. 35 filings are on record since July 8, 2025 (Schedule 13G/A, August 13, 2026).

Oliveira Steven Michael also filed stake reports on 1 other company ↓

Sell to companies like Forte Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-11-04 · Reporting person: Tybourne Capital Management (Hk) Ltd · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-11-04
• Filing 2026-09-08 · Reporting person: Federated Hermes, Inc. · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-09-08
• Filing 2026-08-14 · Reporting person: Orbimed Advisors LLC · Sole voting: 0 · Shared voting: 1,264,980 · Sole dispositive: 0 · Shared dispositive: 1,264,980 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-13 · Reporting person: JANUS HENDERSON GROUP Ltd. · Sole voting: 0 · Shared voting: 1,894,076 · Sole dispositive: 0 · Shared dispositive: 1,894,076 · SCHEDULE 13G/A, 2026-08-13
• Filing 2026-08-13 · Reporting person: Affinity Asset Advisors, LLC · Sole voting: 1,145,391 · Shared voting: 0 · Sole dispositive: 1,145,391 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-13

Forte Biosciences, Inc. has 35 Schedule 13D or 13G filings on record since 2025-07-08. 5 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Forte Biosciences, Inc. and the warning signs.

See Forte Biosciences, Inc.'s free Snapshot Watch Forte Biosciences, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Forte Biosciences, Inc. and the records around it.

Forte Biosciences, Inc. elsewhere on the record

• Who owns it

Companies that share a holder

• Oliveira Steven Michael also filed stake reports on 1 other company: Athira Pharma, Inc. (Oct 2025)
• Alger Associates, Inc. also filed stake reports on 2 other companies: Alger 35 ETF, a series of The Alger ETF Trust (Nov 2026), Cryoport, Inc. (Aug 2025)
• MPM BioImpact LLC also filed stake reports on 4 other companies: Climb Bio, Inc. (Aug 2026), Context Therapeutics Inc. (Aug 2026), DBV TECHNOLOGIES S.A. (Aug 2026)

Want the whole picture on Forte Biosciences, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Forte Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Forte Biosciences, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   35 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Forte Biosciences, Inc. by CUSIP 34962G208 and gives its principal executive office as 3060 PEGASUS PARK DRIVE, BUILDING 6, DALLAS, TX 75247 (SCHEDULE 13G/A, 2026-11-04).

What the percentages are based on

As of June 30, 2026, the Reporting Persons beneficially own approximately 5.6% of the Common Stock outstanding. The percentages disclosed above are based on 20,478,817 shares of Common Stock of the Issuer outstanding as of May 6, 2026, as set forth in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on May 11, 2026.Affinity Asset Advisors, LLC, SCHEDULE 13G/A, 2026-08-13

Timeline

Swipe the table sideways to see every column.

Questions about who owns Forte Biosciences, Inc.

Who owns Forte Biosciences, Inc.?

On this page, 5 holders' latest ownership filings report 5% or more of Forte Biosciences, Inc.: JANUS HENDERSON GROUP Ltd. (9.3%, Schedule 13G/A, filed 2026-08-13), MPM BioImpact LLC (7.2%, Schedule 13G, filed 2026-05-15), Orbimed Advisors LLC (6.2%, Schedule 13G/A, filed 2026-08-14), BlackRock, Inc. (5.9%, Schedule 13G, filed 2026-07-28) and Affinity Asset Advisors, LLC (5.6%, Schedule 13G/A, filed 2026-08-13).

Who are the largest shareholders of Forte Biosciences, Inc.?

By the share each holder's latest filing reports, the largest holders of Forte Biosciences, Inc. on this page are JANUS HENDERSON GROUP Ltd. (9.3%), MPM BioImpact LLC (7.2%) and Orbimed Advisors LLC (6.2%).

When did JANUS HENDERSON GROUP Ltd. buy into Forte Biosciences, Inc.?

The filings give report dates, not purchase dates. The earliest filing from JANUS HENDERSON GROUP Ltd. on this page is the Schedule 13G/A, filed 2026-08-07, reporting 2.5%; its latest, Schedule 13G/A filed 2026-08-13, reports 9.3%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 35 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Tools for this story

Each opens in a new tab, filled in for Forte Biosciences, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Forte Biosciences, Inc. is mentioned again
• Find former Forte Biosciences, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes